Available by prescription only, muromonab-CD3 (Orthoclone OKT®3) is a medicine used to treat organ rejection in people who have a heart, liver, or kidney transplant. A transplant rejection occurs when the immune system recognizes a transplanted organ as foreign and attacks it.
Muromonab-CD3 works by attaching to certain types of white blood cells called T-cells. By attaching to these white blood cells, muromonab-CD3 blocks the action of T-cells to function properly. This suppresses the immune system, helping to stop the T-cells from attacking the newly transplanted organ.
(To learn more about this drug's mechanism of action, click Muromonab-CD3. This article covers several topics, such as dosing guidelines, potential side effects, and general safety precautions to discuss with your healthcare provider before beginning treatment.)
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Food and Drug Administration Web site. Vaccines, Blood and Biologics, Resources for Healthcare Providers. Available at: http://www.fda.gov/BiologicsBloodVaccines/ResourcesforYou/HealthcareProviders/default.htm. Accessed September 30, 2011.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 8th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2008.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click